Inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis afflict over a million Americans. Currently, clinicians have to rely on a frustrating “prescribe and hope” approach until they find the right treatment to control the often debilitating symptoms. Dr. Giles wants to use artificial intelligence to skip the guessing game and determine the best treatment options for new patients based on individual patients’ gene signature.
